MedTrace Logo

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects

NCT04893512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-04-20

No results posted yet for this study

Summary

To evaluate the safety of 2 dose vaccination schedule of orally administered CoV2-OGEN1 In healthy subjects

Conditions

  • SARS-CoV-2 (COVID-19)

Interventions

DRUG

Orally Suspension of CoV2-OGEN1

CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug

Sponsors & Collaborators

  • US Specialty Formulations, LLC

    collaborator UNKNOWN

  • Syneos Health

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
56 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-11-11
Completion
2022-11-11

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893512 on ClinicalTrials.gov